NKX2-5 and neoplasm: Our results demonstrated that combined treatment with NSC232003 and SGI‐1027 led to a more pronounced downregulation of NKX2‐5/LHX1 expression and superior tumor growth inhibition than either inhibitor alone (Figure 6E,F; Figure S7B, Supporting Information), highlighting the potential of this combinatorial therapeutic approach for ESCC management.